Your session is about to expire
← Back to Search
Memantine for Cognitive Impairment After Radiation Therapy in Pediatric Brain Cancer
Study Summary
This trial will test if memantine can help reduce cognitive impairment after radiation therapy in pediatric patients with central nervous system tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 4 trial • 115 Patients • NCT01902004Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your AST and ALT levels must be less than or equal to 2.5 times the upper limit of normal.I am undergoing brain radiation for a primary brain cancer.I have had more than one seizure per month despite taking seizure medication.I have a grade IV brain tumor known as glioblastoma.Your kidney function is within the normal range based on recent blood tests.I am currently taking short-acting benzodiazepines.Your bilirubin levels must be within a certain range, and they will be tested before you can join the study.My brain disease has been confirmed by tests.I have had radiation therapy to my brain before.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.I am over 18 and can consent, or if 7-17, I have my guardian's consent.You have a medical reason or allergy that makes it unsafe for you to take memantine.
- Group 1: Prevention (memantine, CogState)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any prior experiments that have utilized Memantine?
"Currently, 24 medical trials are in progress involving Memantine with 11 of them being Phase 3. Most research is taking place around Ypsilanti, Michigan; however, there are 308 separate sites conducting the study across the US."
How many individuals can participate in this clinical trial?
"Affirmative, the information on clinicaltrials.gov confirms that this experiment is actively recruiting patients. It was first shared to the public on February 17th 2020 and has been updated as recently June 3rd 2022. 20 individuals are being accepted at one medical site for participation in this trial."
Do individuals aged sixty or older fulfill the requirements for participation in this experiment?
"For this research initiative, those aged 4 to 18 are eligible for enrolment."
Is there currently an opportunity for patients to participate in this trial?
"According to the details available on clinicaltrials.gov, this research is actively searching for participants; it was first announced in February of 2020 and its most recent update occurred June 3rd 2022."
What are the eligibility criteria for participation in this clinical trial?
"To meet the qualifications for this medical trial, candidates need to have cancer and must be between 4-18 years old. The study is targeting 20 subjects in total."
Share this study with friends
Copy Link
Messenger